Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas

Systemic treatment options for bone and soft tissue sarcomas remained unchanged until the 2000s. These cancers presented challenges in new drug development partly because of their rarity and heterogeneity. Many new molecular targeting drugs have been tried in the 2010s, and some were approved for bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Kenji, Takahashi, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877600/
https://www.ncbi.nlm.nih.gov/pubmed/29510588
http://dx.doi.org/10.3390/ijms19030739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877600/
https://www.ncbi.nlm.nih.gov/pubmed/29510588
http://dx.doi.org/10.3390/ijms19030739

Ejemplares similares